Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Size: px
Start display at page:

Download "Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49"

Transcription

1 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection of bladder tumor , 153 Bladder cancer cost factors in treatment 142, 143 epidemiology 131 prospects for organ-sparing treatment , 143 radiation therapy efficacy adjuvant therapy rationale 157 external beam radiotherapy comparison with radical cystectomy study limitations 132 radical cystectomy adjuvant therapy studies 133, 134 complication rate 106 continent diversions 133 mortality 106 outcomes stage dependence 110, 111, 114, 115 superficial invasive disease pelvic lymph node involvement dissection 106 prognosis recurrence rate 133 radiochemotherapy adverse effects 126, 127, 142 concerns of organ-sparing approach 127, 128, distant metastases outcome 124 endpoints 120, 121 initial response 121, 122, 129 local control with preserved bladder 123 patient selection 119 post-transurethral resection of bladder 119, , prognostic factors 125, 127 quality of life 142 rationale 118, 119 salvage cystectomy 123, 124, 127 survival and bladder preservation 124, 125, 141, 142 treatment protocol 119, 120, , 141 staging, clinical vs pathological 107, 108, 131 superficial T1G3 cancer natural course prognosis

2 radiation treatment historical series 154, 155 intravesical therapy comparison 156, 157 rationale 154 University of Erlangen series 155, 156 transurethral resection of bladder bacillus Calmette-Guérin adjunct therapy for T1G3 cancer , 153 efficacy 118, 121, 147 treatment challenges 127, 128 Brachytherapy, adverse effects 172 external beam radiation combined with high-dose rate brachytherapy complications 180, 181 patient selection 179, 180 pelvic lymph node radiation transrectal ultrasound guidance 186 radioisotope sources 180 study design and outcomes 178, 179 goals 159 hormone ablation adjuvant therapy limitations 95, 96 interstitial brachytherapy with permanent seed implants morbidity 168, 169 patient selection 169 placement 166 tumor control 166, 167 iodine-125 permanent implants design differential dose-volume histogram 163, 164 dose-volume histogram dosimetric evaluation and reporting 163, 164 placement 162 quality of life outcomes 104 radioisotopes 172, 180 rationale 166 Carboplatin, radiochemotherapy of bladder cancer 122, 125 Chemotherapy, combination therapy 77 corticosteroids 73, 74 docetaxel 76 estramustine phosphate 75 mitomycin 74 mitoxantrone 74 paclitaxel 76 prostate-specific antigen as response marker 72, 73, 77 rationale 72 suramin 73 Chemoradiotherapy, see Bladder cancer Cisplatin, radiochemotherapy of bladder cancer 121, 125, 136, 139, 140 Clinical target volume, conformal threedimensional radiotherapy of prostate cancer 2, 3, 7 Computed tomography, bladder cancer staging 107, 108 Conformal three-dimensional radiotherapy, clinical target volume 2, 3, 7 goals 1 gross tumor volume 2, 17, 18, 20, 22 health-related quality of life 13, 14, 104 high-dose rate brachytherapy combination therapy complications 180, 181 patient selection 179, 180 pelvic lymph node radiation transrectal ultrasound guidance 186 radioisotope sources 180 study design and outcomes 178, 179 historical perspective 26, 171, 172 hormone ablation adjuvant therapy brachytherapy limitations 95, 96 cytoreduction 90 duration 95 early stage disease role 95 Subject Index 193

3 Computed tomography (continued) EORTC trial EORTC trial , 83 EORTC trial , 84 mechanisms and concerns 92 monoclonal antibody study 83, 84 post-radiation 58, 59 pre-radiation 60, 61 Quebec randomized trial 93 rationale 87, 89 RTOG trial 93, 94 synergistic cell killing 90, 91 target volume reduction 94 timing factors 81 hyperthermia with conformal radiotherapy advantages 173 phase II trial outcomes 174, 175 protocol 173, 174 thermosensitivity of tissue 172, 173 intensity modulated radiotherapy beam delivery 29, 30 definition 29 inverse planning 27 29, 178 outcomes 32, 33 planning target volume 6, 31, 32 planning target volume clinical trials, definition and dose prescription 19, 20, 22 definition 3, 4 imaging modalities 18, 22 inter-observer variability 18, 19 margins 5, 6, 17 organ motion 4, 5, 17 prognostic factors 1 radiation dose classification of patients and outcomes 10, 11 escalation studies MD Anderson randomized trial 11, 12 prescription guidelines 6, 7 retrospective studies 11, 12 rationale 25, 26 tumor control probability and radiation dose 87 Corticosteroids, treatment 73, 74 Cystectomy, see Bladder cancer Dethylstilbestrol, treatment 51 Docetaxel, treatment 76 Estramustine phosphate, treatment 75 Estrogens, treatment 51 5-Fluorouracil, radiochemotherapy of bladder cancer 121, 125, 136, 139 Health-related quality of life conformal three-dimensional radiotherapy for 13, 14 radical prostatectomy comparison of different prostate cancer treatment modality outcomes 99, 100, 104 impotence 103 patient education 104 urinary incontinence 100, 101, 103 Hormone ablation therapy, adjuvant and neoadjuvant therapy radiation therapy brachytherapy limitations 95, 96 cytoreduction 90 duration 95 early stage disease role 95 EORTC trial EORTC trial , 83 EORTC trial , 84 mechanisms and concerns 92 monoclonal antibody study 83, 84 post-radiation 58, 59 pre-radiation 60, 61 Quebec randomized trial 93 rationale 87, 89 RTOG trial 93, 94 synergistic cell killing 90, 91 target volume reduction 94 timing factors 81 Subject Index 194

4 radical prostatectomy postsurgery 57, 58 presurgery 59, 60 adverse effects 66 androgen dependence and independence of tumors 66, 67 early vs deferred therapy intermittent therapy continuous therapy comparison 56, 57 early studies 67, 68 phase II trials 68 phase III studies 69, 70 quality of life outcomes maximal androgen blockade 52, 54 monotherapy antiandrogens 52 estrogens 51 luteinizing-releasing hormone analogs 51 orchiectomy 50, 51, 61 survival 49, 66 palliative therapy 171 Hyperthermia with conformal radiotherapy, advantages 173 phase II trial outcomes 174, 175 protocol 173, 174 thermosensitivity of tissue 172, 173 Impotence, radical prostatectomy 103 Intensity modulated radiotherapy beam delivery 29, 30 definition 29 inverse planning 27 29, 178 outcomes 32, 33 planning target volume 6, 31, 32 KONRAD, inverse planning 29 Luteinizing-releasing hormone, prostate cancer treatment with analogs 51, 52, 59, 61, 82, 83 Lymph node radiation, combination therapy 47 patient selection 46, 47 pelvic lymph node radiation with highdose brachytherapy transrectal ultrasound guidance 186 prevalence of node involvement 43 rationale 43 retrospective analysis of pelvic node lymph irradiation biopsy-proven lymph node disease 45, 46 suspected lymph node disease 44 risk factors 43, 44 Magnetic resonance imaging bladder cancer staging 107, 108 clinical target volume 2, 3 planning target volume 18, 22 Mitomycin, treatment 74 Mitoxantrone, treatment 74 Paclitaxel, treatment 76 Pelvic lymph node, see Bladder cancer, Lymph node radiation, Planning target volume, conformal threedimensional radiotherapy of prostate cancer clinical trials, definition and dose prescription 19, 20, 22 definition 3, 4 imaging modalities 18, 22 intensity modulated radiotherapy 6 inter-observer variability 18, 19 margins 5, 6, 17 organ motion 4, 5, 17 Prostate cancer antiandrogen therapy, see Hormone ablation therapy, chemotherapy, see Chemotherapy, prostate cancer Subject Index 195

5 Prostate cancer (continued) epidemiology 171 prostatectomy, see Radical prostatectomy radiotherapy, see Brachytherapy, prostate cancer, Conformal three-dimensional radiotherapy,, Hyperthermia with conformal radiotherapy,, Intensity modulated radiotherapy, Lymph node radiation,, Radical prostatectomy Prostatectomy, see Radical prostatectomy Quality of life, see Health-related quality of life Radical cystectomy, see Bladder cancer Radical prostatectomy cancer recurrence rates 172, 177 health-related quality of life comparison of different treatment modality outcomes 99, 100, 104 impotence 103 patient education 104 urinary incontinence 100, 101, 103 historical perspective 99, 171 hormone ablation adjuvant therapy postsurgery 57, 58 presurgery 59, 60 radiation adjuvant therapy outcomes without radiotherapy 35 percutaneous radiotherapy 36 predictive criteria 38, 39 prostate-specific antigen elevation and outcomes 36 38, 40 side effects 39, 40 Suramin, treatment 73 Transurethral resection of bladder tumor, see Bladder cancer Urinary incontinence radical cystectomy 131 radical prostatectomy 100, 101, 103 Subject Index 196

Definition Prostate cancer

Definition Prostate cancer Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation

More information

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES

More information

When to worry, when to test?

When to worry, when to test? Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Prostate Overview Quiz

Prostate Overview Quiz Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Chapter 18: Glossary

Chapter 18: Glossary Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without

More information

Trimodality Therapy for Muscle Invasive Bladder Cancer

Trimodality Therapy for Muscle Invasive Bladder Cancer Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,

More information

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Urol Clin N Am 31 (2004) 379 387 Index Note: Page numbers of article titles are in boldface type. A Acinar proliferation, atypical small, as markers for risk of development of prostate cancer, 229 Acupuncture,

More information

RADIOTHERAPY IN THE MANAGEMENT OF CANCERS OF THE URINARY BLADDER

RADIOTHERAPY IN THE MANAGEMENT OF CANCERS OF THE URINARY BLADDER RADIOTHERAPY IN THE MANAGEMENT OF CANCERS OF THE URINARY BLADDER INTRODUCTION Incidence: Mortality: 20/100000/year (Europe) 8-9/100000/year Worldwide fourth most common cancer in men Incidence: 31.1 mortality:

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

New Technologies for the Radiotherapy of Prostate Cancer

New Technologies for the Radiotherapy of Prostate Cancer Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to: 1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications

More information

Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review

Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Jayatissa R.M.G.C.S.B. (B.Sc.) Department of Radiography/Radiotherapy, Faculty of Allied Health

More information

Oncological Treatment of Urological Cancer

Oncological Treatment of Urological Cancer Network Guidance Document Oncological Treatment of Urological Cancer Status: Expiry Date: Version Number: Publication Date: Final March 2014 8 March 2012 Page 1 of 13 Contents Contents... 2 Oncology Provision...

More information

General information about prostate cancer

General information about prostate cancer Prostate Cancer General information about prostate cancer Key points Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. Signs of prostate cancer include

More information

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Chapter 5 Stage III and IVa disease

Chapter 5 Stage III and IVa disease Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

GUIDELINEs ON PROSTATE CANCER

GUIDELINEs ON PROSTATE CANCER GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent

More information

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and

More information

20 Prostate Cancer Dan Ash

20 Prostate Cancer Dan Ash 20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised

More information

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk

More information

NAACR Treatment Webinar Quiz 1

NAACR Treatment Webinar Quiz 1 NAACR Treatment Webinar Quiz 1 1. Which of the following would NOT be considered cancer-directed treatment? a. Hemicolectomy b. Incisional biopsy c. Whole breast radiation d. MRI e. All of the above f.

More information

Prostate Cancer in comparison to Radiotherapy alone:

Prostate Cancer in comparison to Radiotherapy alone: Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

External Beam Radiotherapy for Prostate Cancer

External Beam Radiotherapy for Prostate Cancer External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Disclosures. Prostate and Bladder Cancer: Jonathan E. Rosenberg, M.D. U.S. Cancer Statistics: Prostate Cancer Known Risk Factors

Disclosures. Prostate and Bladder Cancer: Jonathan E. Rosenberg, M.D. U.S. Cancer Statistics: Prostate Cancer Known Risk Factors Prostate and Bladder Cancer: 2012 Jonathan E. Rosenberg, M.D. Associate Attending Section Head, Non-Prostate Genitourinary Oncology Service Memorial Sloan-Kettering Cancer Center Disclosures Consulting

More information

Cervical Cancer Guidelines L and SC Network July Introduction:

Cervical Cancer Guidelines L and SC Network July Introduction: Cervical Cancer Guidelines L and SC Network July 2018 Introduction: There was a total number of 442 cases of cervix cancer diagnosed in Lancashire and South Cumbria Cancer Network in the period 2005 2009

More information

NICE BULLETIN Diagnosis & treatment of prostate cancer

NICE BULLETIN Diagnosis & treatment of prostate cancer Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In

More information

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009 Collecting Cancer Data: Prostate NAACCR 2008-2009 Webinar Series June 11, 2009 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview 2008-2009 NAACCR Webinar Series

More information

It is a malignancy originating from breast tissue

It is a malignancy originating from breast tissue 59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast

More information

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...

More information

Appendix 4 Urology Care Pathways

Appendix 4 Urology Care Pathways Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable

More information

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

Urologic Oncology: Seminars and Original Investigations 30 (2012) 3 15

Urologic Oncology: Seminars and Original Investigations 30 (2012) 3 15 Urologic Oncology: Seminars and Original Investigations 30 (2012) 3 15 Review article The multi-disciplinary management of high-risk prostate cancer Jonathan C. Picard, M.D. a, *, Ali-Reza Golshayan, M.D.

More information

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

What is Prostate Cancer?

What is Prostate Cancer? What is Prostate Cancer? Prostate cancer is a malignant tumor that begins in the prostate gland of men. Over 95% of prostate cancers are adenocarcinomas, cancers that develop in glandular tissue. Another

More information

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Organ-sparing treatment of invasive transitional cell bladder carcinoma Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas

More information

Date Modified: May 29, Clinical Quality Measures for PQRS

Date Modified: May 29, Clinical Quality Measures for PQRS Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3

More information

Research Article Gross Hematuria in Patients with Prostate Cancer: Etiology and Management

Research Article Gross Hematuria in Patients with Prostate Cancer: Etiology and Management ISRN Surgery Volume 2013, Article ID 685327, 4 pages http://dx.doi.org/10.1155/2013/685327 Research Article Gross Hematuria in Patients with Prostate Cancer: Etiology and Management Ofer N. Gofrit, 1 Ran

More information

Ακτινοθεραπευτική Ογκολογία & Παθολογική Ογκολογία

Ακτινοθεραπευτική Ογκολογία & Παθολογική Ογκολογία Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical

More information

Partial Cystectomy for Invasive Bladder Cancer

Partial Cystectomy for Invasive Bladder Cancer European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen

More information

The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description

The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description In response to an enquiry from the Scottish Radiotherapy Advisory Group Number 37 June 2011 The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology

More information

ADJUVANT CHEMOTHERAPY...

ADJUVANT CHEMOTHERAPY... Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED

More information

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,

More information

Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan

Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA

More information

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy

More information

Prostate Cancer Treatment

Prostate Cancer Treatment Scan for mobile link. Prostate Cancer Treatment Prostate cancer overview Prostate cancer is the most common form of cancer in American men, most prevalent in men over age 65 and fairly common in men 50-64

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 1. Medical Student Case-Based Learning Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You

More information

Edward P. Gelmann, MD

Edward P. Gelmann, MD Prostate Cancer Edward P. Gelmann, MD Prostate Cancer Etiology and Ep pidemiology Screening Pathology Staging Localized Disease Metastatic Disease normal prostate epithelium GSTP1 CpG island hypermethylation

More information

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National

More information

Prostate cancer. Treatments Side effects and management in the community setting

Prostate cancer. Treatments Side effects and management in the community setting Prostate cancer Treatments Side effects and management in the community setting Kristoffer Ohlin CNS Urology Janice Minter Lead Cancer Nurse St George s Hospital Agenda Prostate cancer treatments Radiotherapy

More information

Oncologist. The. N ews B ulletin. Cancer Medicine: Case Discussions. Progressing Prostate Carcinoma. Joan Karnell Cancer Center Pennsylvania Hospital

Oncologist. The. N ews B ulletin. Cancer Medicine: Case Discussions. Progressing Prostate Carcinoma. Joan Karnell Cancer Center Pennsylvania Hospital The Oncologist N ews B ulletin Cancer Medicine: Case Discussions Joan Karnell Cancer Center Pennsylvania Hospital Progressing Prostate Carcinoma MICHAEL J. HAUT, JOSEPH F. HARRYHILL, JEFFREY ROSENSTOCK,

More information

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008 Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators

More information

Prostate Cancer. What is prostate cancer?

Prostate Cancer. What is prostate cancer? Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum, below the bladder and above the base of the penis. Your doctor may perform

More information

Breast Cancer. What is breast cancer?

Breast Cancer. What is breast cancer? Scan for mobile link. Breast Cancer Breast cancer is a malignant tumor in or around breast tissue. It usually begins as a lump or calcium deposit that develops from abnormal cell growth. Most breast lumps

More information

Hormonal Treatment and other Options in men with locally Advanced Prostate Cancer. Seoul Veterans Hospital Department of Urology Tae Young Jung

Hormonal Treatment and other Options in men with locally Advanced Prostate Cancer. Seoul Veterans Hospital Department of Urology Tae Young Jung Hormonal Treatment and other Options in men with locally Advanced Prostate Cancer Seoul Veterans Hospital Department of Urology Tae Young Jung Introduction Watchful waiting / Androgen deprivation therapy

More information

PET imaging of cancer metabolism is commonly performed with F18

PET imaging of cancer metabolism is commonly performed with F18 PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism

More information

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings. Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year

More information

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although

More information

Prostate cancer: diagnosis and treatment

Prostate cancer: diagnosis and treatment Prostate cancer: diagnosis and treatment Issued: January 2014 NICE clinical guideline 175 guidance.nice.org.uk/cg175 NICE has accredited the process used by the Centre for Clinical Practice at NICE to

More information

Prostate Cancer. David Wilkinson MD Gulfshore Urology

Prostate Cancer. David Wilkinson MD Gulfshore Urology Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)

More information

Measuring the value of healthcare activities. Susan Rollason, Director of Finance and Strategy

Measuring the value of healthcare activities. Susan Rollason, Director of Finance and Strategy Measuring the value of healthcare activities Susan Rollason, Director of Finance and Strategy Items covered What are we doing and why? What have we done so far? What challenges have we faced? What are

More information

Enterprise Interest None

Enterprise Interest None Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information